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Abstract:  
Background: The main goal of this study was to analyse whether initial addition of 
glucocorticoid to DMARD therapy influences the long-term course of the disease in patients 
with early rheumatoid arthritis.  
Method: All patients from the Swiss RA cohort SCQM with recent onset arthritis (disease 
duration ≤1 year) were analysed. The exposure of interest was the use of GCs at baseline. 
As primary outcome we considered clinical and radiographic disease progression, assessed 
by the disease activity (DAS 28), function (HAQ DI) and structural joint damage (Ratingen 
erosion score). The baseline disease characteristics were compared using standard 
descriptive statistics. The effects of initial GC use on disease progression during follow up 
was estimated using linear mixed models with random slope and random intercept, adjusted 
for potential confounders.  
Results: In total, 592 patients with early disease were available, with 4.3 years of follow-up 
(average). Of these, 363 were initially treated with glucocorticoids (GC patients) and 228 
were not (no-GC patients). DAS-28 (4.6 vs. 4.3, p = 0.01) and the HAQ-DI (0.94 vs. 0.82, p = 
0.01) were higher at baseline in GC patients, while other prognostic factors were balanced at 
baseline. Neither the change of DAS-28, of HAQ-DI, nor of the development of joint erosions 
differed between the two groups during follow up. Escalation of treatment employing 
biologics was documented in 18.0% of the no-GC patients and 27.3% of the GC patients (p < 
0.01).  
Conclusion:  
In this cohort, patients with early RA initially treated with GCs had higher measures of 
disease activity at baseline in comparison to no-GC patients. Despite a similar course of the 
disease in GC versus non-GC patients, the higher escalation rate to biologic agents in GC 
patients may reflect a disease less responsive to therapy in these patients.  
These data suggest that GC use as part of the initial therapeutic strategy in early RA may 
prevent a more severe course of the disease in patients with higher clinical disease 
measures at the start of therapy.  
Key words: glucocorticoids, rheumatoid arthritis, disease progression, early disease  
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Significance & Innovation: 
• GC use may have a beneficial role in patients with unfavourable prognostic factors.  
− Patients with initial GC treatment had more unfavourable prognostic factors than those 
without. 
− Early RA patients with and without initial GC use demonstrated similar clinical and 
radiographic development during follow-up. 
• In our opinion, in the absence of contraindications, GCs should always be considered as 
bridging therapy in early disease, and used, in particular, if unfavourable prognostic 
factors are present. 
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Introduction: 
Glucocorticoids (GC) have anti-inflammatory and disease-modifying properties in RA patients 
(1-3). GC treatment added to DMARD therapy is successful at low (<10 mg/day) (4-6) and at 
higher doses (7, 8). Higher doses of GCs lead to a more rapid short-term clinical 
improvement in comparison to patients not treated with GCs at all (7). In the COBRA-light 
study a reduced glucocorticoid dose was equally effective as higher GC doses employed in 
the classical COBRA regimen (9). 
Whether the significantly better outcomes in clinical trials using combinations of synthetic 
DMARDs plus GCs versus DMARD monotherapy might be at least in part be due to the GC 
component (6-8) is under discussion. This hypothesis is supported by studies showing that 
adding GC to DMARD monotherapy(4, 5) is beneficial.  
It is well known that long or even intermediate-term use of GCs can lead to adverse events 
(10). The EULAR task force, therefore, recommends that GCs should be tapered as rapidly 
as possible (11).  
The primary objective of this study was to analyze whether initial corticosteroid therapy 
influences the course of early disease in RA patients. A secondary objective of this study 
was to compare baseline characteristics of early arthritis patients with or without initial GC 
use, possibly explaining the rheumatologist’s decision to add GCs. 
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METHODS: 
Study population and design 
The Swiss Clinical Quality Management in rheumatoid arthritis (SCQM) is a RA national 
cohort study performed by office or hospital based rheumatologists, which has been 
described in detail elsewhere (12, 13). SCQM has obtained a Swiss-wide ethical approval to 
collect patient data and a broad consent to perform clinical research related to its aims. In 
this study, we restricted our analysis to patients with early RA. The analysis includes data 
collected between January 1998 and November 2011. Inclusion criteria for the analysis were 
a diagnosis of RA by a rheumatologist, and early disease, as defined as less than 367 days 
from the first symptoms (as reported by the patient). Patients treated with GCs, synthetic or 
biological DMARDs for more than 31 days before the first visit were excluded from the 
analysis. Exclusion criteria were missing 28 joint counts at baseline or the absence of follow-
up visits, as published before (14, 15).  
Exposure of interest  
The primary objective of the study was to analyse whether initial GC therapy influences the 
course of the disease in early RA patients.  
Outcome parameters  
The primary endpoint was the change of DAS-28 scores. Secondary endpoints were 
changes in radiographic joint damage and patient centred outcomes. The patient centred 
outcome was assessed using the Stanford Health Assessment Questionnaire (HAQ DI) (16). 
Radiographic damage was analyzed on serial radiographs according to the number and the 
size of bone erosions. Erosions were measured prospectively using a validated scoring 
system (Ratingen score) (17), based on the amount of joint-surface destruction for each joint. 
The inter-observer agreement and test-retest reliability were high, as published (17).  
To predict, at baseline, the GC use after 2 years, as a secondary endpoint, all RA patients 
were separated into two groups depending on the documented GC use after two years 
(defined as long-term use of GCs). The two groups were re-analyzed for differences in 
baseline characteristics. 
Statistical analysis 
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The baseline disease characteristics of patients in the two groups were compared using 
standard descriptive statistics. Continuous variables were compared using a Student´s T-
test, categorical variables with X2 test. Curves showing changes in DAS-28 and HAQ DI 
scores over time were created using loess smoothing of the raw data. The effect of initial GC 
use on DAS-28 and HAQ DI scores was estimated using linear mixed models with random 
slope and random intercept, and adjusted for various baseline factors in a univariate fashion, 
as well as in a multivariate fashion considering baseline DAS-28 (or HAQ DI), Ratingen score 
and ESR. We also examined whether GC initiation was influenced by baseline parameters, 
ACR/EULAR classification score, rheumatoid factor, DAS-28, ACPA, ESR, age, gender or 
calendar year of inclusion, in a propensity score analysis using multiple logistic regression. A 
propensity score was then computed as the predicted log-odds of receiving GCs at baseline, 
and included as a univariate predictor in the linear mixed models described above. All 
statistical analyses were 2-sided at the 0.05 significance level. The analyses were performed 
using Graph pad Prism 5 software and the lme4 package in R. 
Ethics approval 
Ethics approval for the collection of patient data for the SCQM Cohort was given by the 
regional review boards. Informed consent was obtained from all patients before inclusion in 
the SCQM Cohort. 
 
Page 7 of 39 Manuscript Submitted to Clinical Rheumatology for Review
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8 
 
RESULTS: 
Patients: 
Of the 9´627 patients in the database, 756 patients had early RA with a symptom duration of 
less than 367 days. 609 patients of these had at least one follow-up in the database, and 592 
patients in the database had valid 28 joint counts. The median follow-up for these 592 
patients was 44 months (range 0 – 178), representing a total of 3’845 visits. 
Baseline demographical data: 
Patients were categorized into two groups: patients treated with GCs (GC patients, n=363) 
and not treated with GC (n=228, no-GC patients) at baseline. Analysis of the demographical 
data revealed no significant differences in age, gender, disease duration, and time of follow 
up between the two patient groups, as shown in Table 1. In 2 patients new treatment was 
initiated within the period of 31 days prior to baseline. Exclusion of these patients from did 
not influence data analysis (not shown). Disease activity was higher at the inclusion visit in 
GC patients. In detail, mean DAS-28 was 4.6 in GC patients vs. 4.3 in no-GC patients (p = 
0.011). Similarly, the ESR was also higher in GC patients (mean 30.5 vs. 24.3mm/h, resp., p 
= 0.0013), whereas CRP (mean 23.7 GC vs. 15.8 no GC, p = 0.13), swollen (7.9 vs. 7.1, p = 
0.09) and tender (8.0 vs. 7.6, p = 0.48) joint count, and erosion scores at disease onset 
showed no statistically significant differences. ACPA and rheumatoid factors also did not 
differ between the two patient groups. The average HAQ DI was higher in GC (0.94) than in 
no-GC patients (0.82, p = 0.0122, Table 1). 
The average GC dose in the GC patients was 14.0mg/d (±9.28)at baseline (median 10mg/d). 
The range was from1.25mg/d to 60mg/d (Figure 1). 
Clinical and radiographic progression: 
Disease activity, patient reported outcome, and development of joint erosions were similar in 
both patient groups during follow up, as demonstrated by DAS-28, HAQ-DI, and erosion 
scores (Figure 2). The time of follow up between the two patient groups did not differ (mean 
171.2 months GC vs. 186.9 months no-GC, p = 0.0529). 
To find out whether GCs were preferentially started in more severe cases of RA, we 
analyzed if GC initiation was associated with the baseline parameters (rheumatoid factor, 
DAS-28, ACPA, ESR, age, gender and calendar year) in a propensity score analysis using 
logistic regression (not shown). After adjusting for this propensity score, no statistically 
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significant difference in clinical activity (difference in DAS-28 0.04 on average, p = 0.67) or 
radiographic disease progression (erosion score 0.75 higher in GC patients, p = 0.29) was 
observed in patients with and without the use of GCs. The same was true for the patient 
oriented outcome (HAQ-DI 0.03 higher in GC patients, p = 0.47). The results were similar 
when using a propensity score from the best-fit model, which included only age and baseline 
ESR. 
Drug survival of initial GCs and new initiation of GCs during follow up: 
The drug survival of GCs after start at baseline was analyzed. GC treatment was stopped in 
301 patients during follow up, after a median of 680 days. In parallel, GC treatment was 
initiated in 48 of the initial no-GC patients after an average of 662 days (Figure 3A). Thus, 
GC treatment was continued in 47.2% of the initial GC patients and started in 21.9% after 2 
years of follow up of the initial no-GC patients (not statistically significant). 
Conventional synthetic DMARD treatment: 
Treatment with conventional synthetic DMARDs was initiated preferentially with methotrexate 
(MTX) in both treatment groups. MTX was a part of the initial therapeutic strategy in 75.5% of 
the GC patients and 66.9% of the no-GC patients (X2 test: 4.492,1, p = 0.03, table 2). The 
average initial MTX doses were 14.4 and 14.1mg/week in the GC and no-GC patients 
respectively (data not shown). In parallel, the first therapeutic modification (independent of 
whether the MTX dose was modified in patients already treated with MTX or whether MTX 
was initiated) was more frequent in GC patients (23.4% in GC vs. 4.7% in no-GC patients, X2 
test: 38.32,1, p < 0.0001). There were no significant differences comparing GC and no-GC 
patients for the use of sulfasalazine, anti-malarials, and leflunomide (data not shown).  
Escalation to biologics: 
Escalation of treatment with biologic agents occurred in 18.0% of the no-GC patients after 
909 days on average and in 27.3% of the GC patients after 754 days (X2 Test for the number 
of patients requiring biologics: 6.96, p = 0.0097, time to first biologic p = 0.31, Figure 3b). 
Co-morbidities: 
Analysis of the number and kind of co-morbidities in our cohort of early RA patients did not 
reveal differences between the two patient groups, neither at baseline, nor during follow up 
(table 3).  
Page 9 of 39 Manuscript Submitted to Clinical Rheumatology for Review
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
 
Predictors for GC use after 2 years 
To explore which baseline parameters were associated with long-term GC treatment, we 
examined patients still on GC after 2 years (table 4). Patients with long-term GC use over 2 
years had an increased HAQ DI of 1.05 at baseline, as compared to 0.86 in those not treated 
with GCs after 2 years (p = 0.005), but no other differences were found for the different 
demographical, serological, and parameters indicative of disease activity or joint destruction.  
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Discussion: 
In this study, we analyzed the effect of initial GC treatment as an adjunct to DMARD therapy 
in a cohort of 592 RA patients with early disease. Patients treated with GCs had higher 
objective and subjective disease activity at the first visit, as measured by the DAS-28 and 
HAQ DI, respectively. These differences evened out during follow up.  
These results may help to shed light on two frequently debated questions:  
• Is the decision for initial treatment with GCs triggered by unfavourable prognostic 
factors? 
• Is GC use from first clinical visit onwards in early RA necessary to modify the further 
course of the disease? 
Is the decision for initial treatment with GCs triggered by unfavourable prognostic 
factors? 
In our study, disease activity (ESR, DAS-28) was higher and functional limitations (HAQ DI) 
were more pronounced in patients initially treated with GCs than in those who were not. The 
most likely explanation is that rheumatologists tended to add concomitant GC preferentially 
to their patients with more severe RA, which is corroborated by the fact that these patients 
also received more frequently biologic anti-rheumatic agents during follow-up than non-GC 
users. 
It is well known that long-term GC treatment is associated with many adverse events. As a 
consequence, rheumatologists try to taper and eventually stop GCs. The reasons for 
maintaining GC treatment for an extended period of time should be well founded and GCs 
should only be used because of a therapeutic necessity in the individual patient. In our study, 
20 – 50% of the patients were still treated with GCs after two years (Figure 3A). The HAQ DI 
at baseline was the only parameter significantly higher in patients on GCs after two years. 
The patient’s individual perception of disease-associated limitations affecting functionality in 
daily life, thus, correlated with the use for GCs after two years.  
Another explanation for initial use of GCs could be the application of predefined therapeutic 
concepts including the use of GCs in all early RA cases by individual rheumatologists or 
centers. However, we could not demonstrate an association between the initial use of GCs 
and individual rheumatologists or centers involved (data not shown), suggesting that GC use 
was no related to a strong physician bias as in a natural study.  
 
Is the GC use from first clinical visit onwards in early RA necessary to modify the 
further course of the disease? 
In view of the loss of the initial differences in disease activity during follow up, our data 
suggest -at first sight - that the initial use of GCs does not improve long-term results.  
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No differences between patients initially treated or not with GCs in radiographic progression, 
DAS-28 or HAQ DI could be found. However, biologic agents were more frequently initiated 
during follow up in GC- than in no-GC patients, most probably reflecting an initial clinical 
disease state less responsive to therapy in these patients. GC may only be necessary in 
patients with higher baseline DAS and HAQ-DI scores.  
A considerable number of clinical studies (18) has demonstrated that more aggressive 
treatment may lead to better results (19). Increased baseline parameters such as ESR, high 
joint counts as part of the DAS-28 and HAQ DI are known to have a negative influence on 
the course of RA (20, 21) . These parameters were higher in the GC group (22) of our cohort, 
indicating a potential for more aggressive disease. Considering the equal course of disease 
in the two patient groups, GCs may actually have prevented a more severe course of the 
disease. In the EULAR guidelines recommend that “low-dose glucocorticoids” should ideally 
be considered ”as part of the initial treatment strategy” since addition of GCs to DMARD 
therapy as “bridging therapy” has been shown to have a similar effect as the addition of a 
TNF antagonist to MTX (11, 23-25). In view of the multitude of parameters involved, data 
derived from clinical cohorts are never unequivocal. Our analysis, however, may support the 
use of GC in early RA in patients with higher clinical disease measures such as higher DAS-
28, ESR and HAQ-DI (high DAS-28, ESR, and HAQ-DI, (20, 21)). This conclusion is similar to 
the statement in the EULAR guidelines in Phase II for the therapeutic decision after the first 
DMARD has failed (11). These recommendations propose a second synthetical DMARDs in 
patients with favourable and a first biologic agents in those with unfavourable prognostic 
factors.  
Health economic considerations: 
The percentage of 27% GC- and 15% no-GC-patients requiring a step up of therapy to a 
biologic agent appeared rather low. A possible reason for this may have been the relatively 
early recruitment period of January 1998 and November 2011(median May 15th 2005) in our 
cohort. However, this rate is comparable to others published by Fiehn et al. in Germany for 
the time period 1997 – 2005 or, more recently, for the Dutch tREACH cohort (23, 26). 
Considering yearly costs of CHF 21´232,90 for a biologic agent (e.g. Adalimumab, 
Switzerland OTC price) and CHF 119,-- for 10 mg prednisolone (e.g. Spiricort, Switzerland 
OTC price), reduction of biologic agents by e.g. 5% would be equivalent to overall savings of 
CHF 94´265 (in 100 patients). Or, in other words, the costs would be equivalent if 178 early 
RA patients are treated continuously with prednisolone over one year and in one patient out 
of these 178 therapy is not escalated a biologic agent. These considerations are, as a matter 
of course, purely economic and do not take into account costs caused by therapy related 
side effects of either corticosteroids or biologics. 
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Limitation: 
GCs are frequently associated with AEs. Assessment of AEs is certainly an issue for the 
analysis of cohort data. We have analysed the adverse event rate in both groups and found 
no differences between the two groups (data not shown). The relative risk for a comorbidity 
was 1.12 comparing GC and no GC patients. The leads to a number needed to harm (NNH) 
of 1960.1. However, the rate of AEs was very low and we think that underreporting of AEs is 
a major bias to this analysis.  
The initial glucocorticoid doses employed in the GC patients varied from 1.25 to 60mg/d at 
onset of treatment. The improved effect of higher initial GC doses has been reviewed by 
Laan et al. (27). However, it cannot be derived from the database whether the physicians 
coded the GC dose initiated or, rather, the dose reached after initial tapering. Therefore, no 
conclusions can be drawn from our data on the initial GC dose used and its effect on the 
course of the disease. 
 
Summary and conclusions: 
Patients with initial GC treatment had more unfavourable prognostic factors than those 
without, implying a more aggressive evolution of their disease. However, early RA patients 
with and without initial GC use demonstrated similar clinical and radiographic evolution, 
suggesting that initial GC use may have had a beneficial role in these patients with 
unfavourable prognostic factors. In our opinion, in the absence of contraindications, GCs 
should be considered as bridging therapy in early disease  in particular, if prognostic factors 
of severe disease are present. 
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Tables, Figure legends: 
Table 1: Patient baseline characteristics 
GC use initiated at baseline Present Not present P value 
Number 363 228 - 
Age (years, mean ± SD) 55.1 ± 14.8 51.3 ± 15.2 0.034 
Gender (f/m) 257/106 172/56 0.214 
Follow-up (months, mean ± SD) 51.4 ± 37.2 50.6 ± 39.1 0.80 
Symptom durations (days, mean ± 
SD) 
171.2 ± 98.5 186.9 ± 94.5 0.0529 
SJC at onset (mean ± SD) 7.9 ±6.0 7.1 ± 5.9 0.088 
TJC at onset (mean ± SD) 8.0 ± 6.8 7.6 ±6.6 0.48 
DAS-28 at onset (mean ± SD) 4.6 ± 1.6 4.3 ± 1.6 0.011 
RF pos. at onset (n, %*) 231, 63.6% 157, 68.9% 0.19 
CCP pos. at onset (n, %*) 85, 62.0% 66, 65.3% 0.60 
ESR at onset, mm/h (mean ± SD) 30.5 ± 25.3 24.3 ± 20.4 0.0013 
CRP at onset, mg/l (mean ± SD) 23.7 ± 12.1 15.8 ± 11.5 0.13 
Ratingen score at onset 8.9 ± 9.6 7.1 ± 8.4 0.0614 
HAQ-DI at onset 0.94 ± 0.71 0.82 ± 0.65 0.0122 
Initial GC dose (av. mg ± SD, range, 
median) 
14.1 ± 9.8, 
2.5-50, 10 
0 ± 0, 0 - 
f: female  
GC: Glucocortioid 
m: male 
TJC: Tender joint count 
SJC: Swollen joint count 
RF: rheumatoid factor 
CCP: antibodies to cyclic citrullinated peptides 
CRP: C reactive protein 
n.a. not applicable 
LORA: Late onset rheumatoid arthritis (>60a) 
YORA: Young onset rheumatoid arthritis (<60a) 
• Calculated on patients with available data  
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 Table 2: Percentage of patients on certain drug therapy (%) 
  
MTX SSZ Lef HCQ 
Initial therapeutic 
strategy 
No-GC 66.9 10.5 6.8 6.0 
GC 75.5 12.0 4.6 9.8 
1
st
 modification of initial 
therapy 
No-GC 4.7 6.0 5.5 6.9 
GC 23.4 7.2 11.0 6.3 
2
nd
 modification of 
initial therapy 
No-GC 6.1 4.4 6.1 2.2 
GC 9.2 4.4 4.1 3.6 
3
rd
 modification of 
initial therapy 
No-GC 5.3 0 1.8 1.3 
GC 4.4 0.6 5.2 1.9 
4
th
 modification of initial 
therapy 
No-GC 1.3 0.4 1.3 0.9 
GC 1.3 0.6 2.2 0.8 
No-GC: Patients initially treated with glucocorticoids 
GC: Patients initially treated without glucocorticoids 
MTX: Methotrexate 
SSZ: Sulfasalazine 
Lef: Leflunomide 
HCQ: Hydroxychloroquine 
 
Table 3: Comorbidities: 
  GC no-GC 
Total n = 92 n = 51 
Allergical n = 11 n = 5 
Cardiological n = 5 n = 2 
Dermatological n = 18 n = 7 
Gastrointestinal n = 24 n = 16 
General n = 2 n = 4 
Hematological n = 1 n = 3 
Hepatical n = 1 - 
Ears, nose, through n = 2 n = 2 
Infectious n = 8 n = 4 
Musculosceletal n = 2 - 
Neoplasia n = 1 n = 3 
Nephrological n =1 - 
Nephrological - n = 1 
Neuropsychiatric n = 8 n = 1 
Not defined n = 3 n = 1 
Ophthalmologic n = 1 - 
Pulmonary n = 4 n = 2 
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Table 4: Patient characteristics at baseline depending on the GC use after two years 
GC used after 2 years still on GC no-GC P value 
Number 153 439 - 
Age (years, mean ± SD) 54.6 ± 15.1 53.3 ± 15.1 0.37 
Gender (f/m) 112/41 317/122 0.06 
Follow-up (months, mean ± SD) 63.7 ± 36.5 46.8 ± 37.5 <0.0001 
Disease durations (days, mean ± SD) 181.2 ± 99.7 175.8 ± 96.4 0.56 
SJC at onset (mean ± SD) 7.8 ± 6.1 7.5 ± 5.9 0.66 
TJC at onset (mean ± SD) 8.3 ± 7.2 7.7 ± 6.5 0.32 
DAS-28 at onset (mean ± SD) 4.6 ± 1.6 4.5 ± 1.5 0.30 
RF pos. at onset (n, %*) 107, 69.9 % 281, 64.0%   0.18 
CCP pos. at onset (n, %*) 35, 62.5% 116, 63.4% 0.90 
ESR at onset, mm/h (mean ± SD) 31.2 ± 24.8 27.1 ± 23.3 0.08 
CRP at onset, mg/l (mean ± SD) 27.0 ± 9.1 19.3 ± 12.6 0.45 
Ratingen score at onset 8.1 ± 8.6 8.4 ± 8.6 0.74 
HAQ-DI at onset 1.05 ± 0.73 0.86 ± 0.67 0.005 
f: female 
GC: Glucocorticoids  
m: male 
TJC: Tender joint count 
SJC: Swollen joint count 
RF: rheumatoid factor 
CCP: antibodies to cyclic citrullinated peptides 
CRP: C reactive protein 
n.a. not applicable 
LORA: Late onset rheumatoid arthritis (>60a) 
YORA: Young onset rheumatoid arthritis (<60a) 
* Calculated on patients with available data  
Figure 1: Average GC doses. The average GC doses are demonstrated depending on the 
number of patients initiated on the respected dose 
  
Figure 2: DAS-28, HAQ scores and radiographic progression over time. Patient groups 
were analyzed separately for initial GC (dotted grey line, GC patients) and no initial GC use 
(solid black line, no-GC patients). Loess smoothed time-courses of DAS-28 (A), Ratingen 
(B), and (C) HAQ DI scores are depicted per group over 60 months of follow-up.  
 
Figure 3. Time to stop/start glucocorticoids and time to start the first biologic DMARD. 
(A) The time to stop glucocorticoids (black line) and the time to start glucocorticoids (grey 
line) in patients initiated with GC (black line) and patients initiated without GCs (grey line). 
The time was assessed in days from the first documented therapy for RA in our cohort within 
the SCQM registry. Patients are presented as percentage of either group. (B) The time to 
initiation of the first biologic DMARD was shown in days after the first visit in patients initiated 
without glucocorticoids (black line) and patients initiated without GCs (grey line). Data was 
shown as percentage per patient group. The time to biologic is demonstrated as days after 
the first visit. 
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Figure 1: Average GC doses. The average GC doses are demonstrated depending on the number of patients 
initiated on the respected dose  
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Figure 2: DAS-28, HAQ scores and radiographic progression over time. Patient groups were analyzed 
separately for initial GC (dotted grey line, GC patients) and no initial GC use (solid black line, no-GC 
patients). Loess smoothed time-courses of DAS-28 (A), Ratingen (B), and (C) HAQ DI scores are depicted 
per group over 60 months of follow-up.  
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Figure 3. Time to stop/start glucocorticoids and time to start the first biologic DMARD. (A) The time to stop 
glucocorticoids (black line) and the time to start glucocorticoids (grey line) in patients initiated with GC 
(black line) and patients initiated without GCs (grey line). The time was assessed in days from the first 
documented therapy for RA in our cohort within the SCQM registry. Patients are presented as percentage of 
either group. (B) The time to initiation of the first biologic DMARD was shown in days after the first visit in 
patients initiated without glucocorticoids (black line) and patients initiated without GCs (grey line). Data was 
shown as percentage per patient group. The time to biologic is demonstrated as days after the first visit.  
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Abstract:  
Background: The main goal of this study was to analyse whether initial addition of 
glucocorticoid to DMARD therapy influences the long-term course of the disease in patients 
with early rheumatoid arthritis.  
Method: All patients from the Swiss RA cohort SCQM with recent onset arthritis (disease 
duration ≤1 year) were analysed. The exposure of interest was the use of GCs at baseline. 
As primary outcome we considered clinical and radiographic disease progression, assessed 
by the disease activity (DAS 28), function (HAQ DI) and structural joint damage (Ratingen 
erosion score). The baseline disease characteristics were compared using standard 
descriptive statistics. The effects of initial GC use on disease progression during follow up 
was estimated using linear mixed models with random slope and random intercept, adjusted 
for potential confounders.  
Results: In total, 592 patients with early disease were available, with 4.3 years of follow-up 
(average). Of these, 363 were initially treated with glucocorticoids (GC patients) and 228 
were not (no-GC patients). DAS-28 (4.6 vs. 4.3, p = 0.01) and the HAQ-DI (0.94 vs. 0.82, p = 
0.01) were higher at baseline in GC patients, while other prognostic factors were balanced at 
baseline. Neither the change of DAS-28, of HAQ-DI, nor of the development of joint erosions 
differed between the two groups during follow up. Escalation of treatment employing 
biologics was documented in 18.0% of the no-GC patients and 27.3% of the GC patients (p < 
0.01).  
Conclusion:  
In this cohort, patients with early RA initially treated with GCs had higher measures of 
disease activity at baseline in comparison to no-GC patients. Despite a similar course of the 
disease in GC versus non-GC patients, the higher escalation rate to biologic agents in GC 
patients may reflect a disease less responsive to therapy in these patients.  
These data suggest that GC use as part of the initial therapeutic strategy in early RA may 
prevent a more severe course of the disease in patients with higher clinical disease 
measures at the start of therapy.  
Key words: glucocorticoids, rheumatoid arthritis, disease progression, early disease  
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Significance & Innovation: 
• GC use may have a beneficial role in patients with unfavourable prognostic factors.  
− Patients with initial GC treatment had more unfavourable prognostic factors than those 
without. 
− Early RA patients with and without initial GC use demonstrated similar clinical and 
radiographic development during follow-up. 
• In our opinion, in the absence of contraindications, GCs should always be considered as 
bridging therapy in early disease, and used, in particular, if unfavourable prognostic 
factors are present. 
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Introduction: 
Glucocorticoids (GC) have anti-inflammatory and disease-modifying properties in RA patients 
(1-3). GC treatment added to DMARD therapy is successful at low (<10 mg/day) (4-6) and at 
higher doses (7, 8). Higher doses of GCs lead to a more rapid short-term clinical 
improvement in comparison to patients not treated with GCs at all (7). In the COBRA-light 
study a reduced glucocorticoid dose was equally effective as higher GC doses employed in 
the classical COBRA regimen (9). 
Whether the significantly better outcomes in clinical trials using combinations of synthetic 
DMARDs plus GCs versus DMARD monotherapy might be at least in part be due to the GC 
component (6-8) is under discussion. This hypothesis is supported by studies showing that 
adding GC to DMARD monotherapy(4, 5) is beneficial.  
It is well known that long or even intermediate-term use of GCs can lead to adverse events 
(10). The EULAR task force, therefore, recommends that GCs should be tapered as rapidly 
as possible (11).  
The primary objective of this study was to analyze whether initial corticosteroid therapy 
influences the course of early disease in RA patients. A secondary objective of this study 
was to compare baseline characteristics of early arthritis patients with or without initial GC 
use, possibly explaining the rheumatologist’s decision to add GCs. 
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METHODS: 
Study population and design 
The Swiss Clinical Quality Management in rheumatoid arthritis (SCQM) is a RA national 
cohort study performed by office or hospital based rheumatologists, which has been 
described in detail elsewhere (12, 13). SCQM has obtained a Swiss-wide ethical approval to 
collect patient data and a broad consent to perform clinical research related to its aims. In 
this study, we restricted our analysis to patients with early RA. The analysis includes data 
collected between January 1998 and November 2011. Inclusion criteria for the analysis were 
a diagnosis of RA by a rheumatologist, and early disease, as defined as less than 367 days 
from the first symptoms (as reported by the patient). Patients treated with GCs, synthetic or 
biological DMARDs for more than 31 days before the first visit were excluded from the 
analysis. Exclusion criteria were missing 28 joint counts at baseline or the absence of follow-
up visits, as published before (14, 15).  
Exposure of interest  
The primary objective of the study was to analyse whether initial GC therapy influences the 
course of the disease in early RA patients.  
Outcome parameters  
The primary endpoint was the change of DAS-28 scores. Secondary endpoints were 
changes in radiographic joint damage and patient centred outcomes. The patient centred 
outcome was assessed using the Stanford Health Assessment Questionnaire (HAQ DI) (16). 
Radiographic damage was analyzed on serial radiographs according to the number and the 
size of bone erosions. Erosions were measured prospectively using a validated scoring 
system (Ratingen score) (17), based on the amount of joint-surface destruction for each joint. 
The inter-observer agreement and test-retest reliability were high, as published (17).  
To predict, at baseline, the GC use after 2 years, as a secondary endpoint, all RA patients 
were separated into two groups depending on the documented GC use after two years 
(defined as long-term use of GCs). The two groups were re-analyzed for differences in 
baseline characteristics. 
Statistical analysis 
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The baseline disease characteristics of patients in the two groups were compared using 
standard descriptive statistics. Continuous variables were compared using a Student´s T-
test, categorical variables with X2 test. Curves showing changes in DAS-28 and HAQ DI 
scores over time were created using loess smoothing of the raw data. The effect of initial GC 
use on DAS-28 and HAQ DI scores was estimated using linear mixed models with random 
slope and random intercept, and adjusted for various baseline factors in a univariate fashion, 
as well as in a multivariate fashion considering baseline DAS-28 (or HAQ DI), Ratingen score 
and ESR. We also examined whether GC initiation was influenced by baseline parameters, 
ACR/EULAR classification score, rheumatoid factor, DAS-28, ACPA, ESR, age, gender or 
calendar year of inclusion, in a propensity score analysis using multiple logistic regression. A 
propensity score was then computed as the predicted log-odds of receiving GCs at baseline, 
and included as a univariate predictor in the linear mixed models described above. All 
statistical analyses were 2-sided at the 0.05 significance level. The analyses were performed 
using Graph pad Prism 5 software and the lme4 package in R. 
Ethics approval 
Ethics approval for the collection of patient data for the SCQM Cohort was given by the 
regional review boards. Informed consent was obtained from all patients before inclusion in 
the SCQM Cohort. 
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RESULTS: 
Patients: 
Of the 9´627 patients in the database, 756 patients had early RA with a symptom duration of 
less than 367 days. 609 patients of these had at least one follow-up in the database, and 592 
patients in the database had valid 28 joint counts. The median follow-up for these 592 
patients was 44 months (range 0 – 178), representing a total of 3’845 visits. 
Baseline demographical data: 
Patients were categorized into two groups: patients treated with GCs (GC patients, n=363) 
and not treated with GC (n=228, no-GC patients) at baseline. Analysis of the demographical 
data revealed no significant differences in age, gender, disease duration, and time of follow 
up between the two patient groups, as shown in Table 1. In 2 patients new treatment was 
initiated within the period of 31 days prior to baseline. Exclusion of these patients from did 
not influence data analysis (not shown). Disease activity was higher at the inclusion visit in 
GC patients. In detail, mean DAS-28 was 4.6 in GC patients vs. 4.3 in no-GC patients (p = 
0.011). Similarly, the ESR was also higher in GC patients (mean 30.5 vs. 24.3mm/h, resp., p 
= 0.0013), whereas CRP (mean 23.7 GC vs. 15.8 no GC, p = 0.13), swollen (7.9 vs. 7.1, p = 
0.09) and tender (8.0 vs. 7.6, p = 0.48) joint count, and erosion scores at disease onset 
showed no statistically significant differences. ACPA and rheumatoid factors also did not 
differ between the two patient groups. The average HAQ DI was higher in GC (0.94) than in 
no-GC patients (0.82, p = 0.0122, Table 1). 
The average GC dose in the GC patients was 14.0mg/d (±9.28)at baseline (median 10mg/d). 
The range was from1.25mg/d to 60mg/d (Figure 1). 
Clinical and radiographic progression: 
Disease activity, patient reported outcome, and development of joint erosions were similar in 
both patient groups during follow up, as demonstrated by DAS-28, HAQ-DI, and erosion 
scores (Figure 1Figure 2). The time of follow up between the two patient groups did not differ 
(mean 171.2 months GC vs. 186.9 months no-GC, p = 0.0529). 
To find out whether GCs were preferentially started in more severe cases of RA, we 
analyzed if GC initiation was associated with the baseline parameters (rheumatoid factor, 
DAS-28, ACPA, ESR, age, gender and calendar year) in a propensity score analysis using 
logistic regression (not shown). After adjusting for this propensity score, no statistically 
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significant difference in clinical activity (difference in DAS-28 0.04 on average, p = 0.67) or 
radiographic disease progression (erosion score 0.75 higher in GC patients, p = 0.29) was 
observed in patients with and without the use of GCs. The same was true for the patient 
oriented outcome (HAQ-DI 0.03 higher in GC patients, p = 0.47). The results were similar 
when using a propensity score from the best-fit model, which included only age and baseline 
ESR. 
Drug survival of initial GCs and new initiation of GCs during follow up: 
The drug survival of GCs after start at baseline was analyzed. GC treatment was stopped in 
301 patients during follow up, after a median of 680 days. In parallel, GC treatment was 
initiated in 48 of the initial no-GC patients after an average of 662 days (Fig.Figure 2A3A). 
Thus, GC treatment was continued in 47.2% of the initial GC patients and started in 21.9% 
after 2 years of follow up of the initial no-GC patients (not statistically significant). 
Conventional synthetic DMARD treatment: 
Treatment with conventional synthetic DMARDs was initiated preferentially with methotrexate 
(MTX) in both treatment groups. MTX was a part of the initial therapeutic strategy in 75.5% of 
the GC patients and 66.9% of the no-GC patients (X2 test: 4.492,1, p = 0.03, table 2). The 
average initial MTX doses were 14.4 and 14.1mg/week in the GC and no-GC patients 
respectively (data not shown). In parallel, the first therapeutic modification (independent of 
whether the MTX dose was modified in patients already treated with MTX or whether MTX 
was initiated) was more frequent in GC patients (23.4% in GC vs. 4.7% in no-GC patients, X2 
test: 38.32,1, p < 0.0001). There were no significant differences comparing GC and no-GC 
patients for the use of sulfasalazine, anti-malarials, and leflunomide (data not shown).  
Escalation to biologics: 
Escalation of treatment with biologic agents occurred in 18.0% of the no-GC patients after 
909 days on average and in 27.3% of the GC patients after 754 days (X2 Test for the number 
of patients requiring biologics: 6.96, p = 0.0097, time to first biologic p = 0.31, Fig.Figure 
2b3b). 
Co-morbidities: 
Analysis of the number and kind of co-morbidities in our cohort of early RA patients did not 
reveal differences between the two patient groups, neither at baseline, nor during follow up 
(table 3).  
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Predictors for GC use after 2 years 
To explore which baseline parameters were associated with long-term GC treatment, we 
examined patients still on GC after 2 years (table 4). Patients with long-term GC use over 2 
years had an increased HAQ DI of 1.05 at baseline, as compared to 0.86 in those not treated 
with GCs after 2 years (p = 0.005), but no other differences were found for the different 
demographical, serological, and parameters indicative of disease activity or joint destruction.  
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Discussion: 
In this study, we analyzed the effect of initial GC treatment as an adjunct to DMARD therapy 
in a cohort of 592 RA patients with early disease. Patients treated with GCs had higher 
objective and subjective disease activity at the first visit, as measured by the DAS-28 and 
HAQ DI, respectively. These differences evened out during follow up.  
These results may help to shed light on two frequently debated questions:  
• Is the decision for initial treatment with GCs triggered by unfavourable prognostic 
factors? 
• Is GC use from first clinical visit onwards in early RA necessary to modify the further 
course of the disease? 
Is the decision for initial treatment with GCs triggered by unfavourable prognostic 
factors? 
In our study, disease activity (ESR, DAS-28) was higher and functional limitations (HAQ DI) 
were more pronounced in patients initially treated with GCs than in those who were not. The 
most likely explanation is that rheumatologists tended to add concomitant GC preferentially 
to their patients with more severe RA, which is corroborated by the fact that these patients 
also received more frequently biologic anti-rheumatic agents during follow-up than non-GC 
users. 
It is well known that long-term GC treatment is associated with many adverse events. As a 
consequence, rheumatologists try to taper and eventually stop GCs. The reasons for 
maintaining GC treatment for an extended period of time should be well founded and GCs 
should only be used because of a therapeutic necessity in the individual patient. In our study, 
20 – 50% of the patients were still treated with GCs after two years (Fig.Figure 2 3A). The 
HAQ DI at baseline was the only parameter significantly higher in patients on GCs after two 
years. The patient’s individual perception of disease-associated limitations affecting 
functionality in daily life, thus, correlated with the use for GCs after two years.  
Another explanation for initial use of GCs could be the application of predefined therapeutic 
concepts including the use of GCs in all early RA cases by individual rheumatologists or 
centers. However, we could not demonstrate an association between the initial use of GCs 
and individual rheumatologists or centers involved (data not shown), suggesting that GC use 
was no related to a strong physician bias as in a natural study.  
 
Is the GC use from first clinical visit onwards in early RA necessary to modify the 
further course of the disease? 
In view of the loss of the initial differences in disease activity during follow up, our data 
suggest -at first sight - that the initial use of GCs does not improve long-term results.  
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No differences between patients initially treated or not with GCs in radiographic progression, 
DAS-28 or HAQ DI could be found. However, biologic agents were more frequently initiated 
during follow up in GC- than in no-GC patients, most probably reflecting an initial clinical 
disease state less responsive to therapy in these patients. GC may only be necessary in 
patients with higher baseline DAS and HAQ-DI scores.  
A considerable number of clinical studies (18) has demonstrated that more aggressive 
treatment may lead to better results (19). Increased baseline parameters such as ESR, high 
joint counts as part of the DAS-28 and HAQ DI are known to have a negative influence on 
the course of RA (20, 21) . These parameters were higher in the GC group (22) of our cohort, 
indicating a potential for more aggressive disease. Considering the equal course of disease 
in the two patient groups, GCs may actually have prevented a more severe course of the 
disease. In the EULAR guidelines recommend that “low-dose glucocorticoids” should ideally 
be considered ”as part of the initial treatment strategy” since addition of GCs to DMARD 
therapy as “bridging therapy” has been shown to have a similar effect as the addition of a 
TNF antagonist to MTX (11, 23-25). In view of the multitude of parameters involved, data 
derived from clinical cohorts are never unequivocal. Our analysis, however, may support the 
use of GC in early RA in patients with higher clinical disease measures such as higher DAS-
28, ESR and HAQ-DI (high DAS-28, ESR, and HAQ-DI, (20, 21)). This conclusion is similar to 
the statement in the EULAR guidelines in Phase II for the therapeutic decision after the first 
DMARD has failed (11). These recommendations propose a second synthetical DMARDs in 
patients with favourable and a first biologic agents in those with unfavourable prognostic 
factors.  
Health economic considerations: 
The percentage of 27% GC- and 15% no-GC-patients requiring a step up of therapy to a 
biologic agent appeared rather low. A possible reason for this may have been the relatively 
early recruitment period of January 1998 and November 2011(median May 15th 2005) in our 
cohort. However, this rate is comparable to others published by Fiehn et al. in Germany for 
the time period 1997 – 2005 or, more recently, for the Dutch tREACH cohort (23, 26). 
Considering yearly costs of CHF 21´232,90 for a biologic agent (e.g. Adalimumab, 
Switzerland OTC price) and CHF 119,-- for 10 mg prednisolone (e.g. Spiricort, Switzerland 
OTC price), reduction of biologic agents by e.g. 5% would be equivalent to overall savings of 
CHF 94´265 (in 100 patients). Or, in other words, the costs would be equivalent if 178 early 
RA patients are treated continuously with prednisolone over one year and in one patient out 
of these 178 therapy is not escalated a biologic agent. These considerations are, as a matter 
of course, purely economic and do not take into account costs caused by therapy related 
side effects of either corticosteroids or biologics. 
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Limitation: 
GCs are frequently associated with AEs. Assessment of AEs is certainly an issue for the 
analysis of cohort data. We have analysed the adverse event rate in both groups and found 
no differences between the two groups (data not shown). The relative risk for a comorbidity 
was 1.12 comparing GC and no GC patients. The leads to a number needed to harm (NNH) 
of 1960.1. However, the rate of AEs was very low and we think that underreporting of AEs is 
a major bias to this analysis.  
The initial glucocorticoid doses employed in the GC patients varied from 1.25 to 60mg/d at 
onset of treatment. The improved effect of higher initial GC doses has been reviewed by 
Laan et al. (27). However, it cannot be derived from the database whether the physicians 
coded the GC dose initiated or, rather, the dose reached after initial tapering. Therefore, no 
conclusions can be drawn from our data on the initial GC dose used and its effect on the 
course of the disease. 
 
Summary and conclusions: 
Patients with initial GC treatment had more unfavourable prognostic factors than those 
without, implying a more aggressive evolution of their disease. However, early RA patients 
with and without initial GC use demonstrated similar clinical and radiographic evolution, 
suggesting that initial GC use may have had a beneficial role in these patients with 
unfavourable prognostic factors. In our opinion, in the absence of contraindications, GCs 
should always be considered as bridging therapy in early disease, and used,  in particular, if 
prognostic factors of severe disease are present. 
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Tables, Figure legends: 
Table 1: Patient baseline characteristics 
GC use initiated at baseline Present Not present P value 
Number 363 228 - 
Age (years, mean ± SD) 55.1 ± 14.8 51.3 ± 15.2 0.034 
Gender (f/m) 257/106 172/56 0.214 
Follow-up (months, mean ± SD) 51.4 ± 37.2 50.6 ± 39.1 0.80 
Symptom durations (days, mean ± 
SD) 
171.2 ± 98.5 186.9 ± 94.5 0.0529 
SJC at onset (mean ± SD) 7.9 ±6.0 7.1 ± 5.9 0.088 
TJC at onset (mean ± SD) 8.0 ± 6.8 7.6 ±6.6 0.48 
DAS-28 at onset (mean ± SD) 4.6 ± 1.6 4.3 ± 1.6 0.011 
RF pos. at onset (n, %*) 231, 63.6% 157, 68.9% 0.19 
CCP pos. at onset (n, %*) 85, 62.0% 66, 65.3% 0.60 
ESR at onset, mm/h (mean ± SD) 30.5 ± 25.3 24.3 ± 20.4 0.0013 
CRP at onset, mg/l (mean ± SD) 23.7 ± 12.1 15.8 ± 11.5 0.13 
Ratingen score at onset 8.9 ± 9.6 7.1 ± 8.4 0.0614 
HAQ-DI at onset 0.94 ± 0.71 0.82 ± 0.65 0.0122 
Initial GC dose (av. mg ± SD, range, 
median) 
14.1 ± 9.8, 
2.5-50, 10 
0 ± 0, 0 - 
f: female  
GC: Glucocortioid 
m: male 
TJC: Tender joint count 
SJC: Swollen joint count 
RF: rheumatoid factor 
CCP: antibodies to cyclic citrullinated peptides 
CRP: C reactive protein 
n.a. not applicable 
LORA: Late onset rheumatoid arthritis (>60a) 
YORA: Young onset rheumatoid arthritis (<60a) 
• Calculated on patients with available data  
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 Table 2: Percentage of patients on certain drug therapy (%) 
  
MTX SSZ Lef HCQ 
Initial therapeutic 
strategy 
No-GC 66.9 10.5 6.8 6.0 
GC 75.5 12.0 4.6 9.8 
1
st
 modification of initial 
therapy 
No-GC 4.7 6.0 5.5 6.9 
GC 23.4 7.2 11.0 6.3 
2
nd
 modification of 
initial therapy 
No-GC 6.1 4.4 6.1 2.2 
GC 9.2 4.4 4.1 3.6 
3
rd
 modification of 
initial therapy 
No-GC 5.3 0 1.8 1.3 
GC 4.4 0.6 5.2 1.9 
4
th
 modification of initial 
therapy 
No-GC 1.3 0.4 1.3 0.9 
GC 1.3 0.6 2.2 0.8 
No-GC: Patients initially treated with glucocorticoids 
GC: Patients initially treated without glucocorticoids 
MTX: Methotrexate 
SSZ: Sulfasalazine 
Lef: Leflunomide 
HCQ: Hydroxychloroquine 
 
Table 3: Comorbidities: 
  GC no-GC 
Total n = 92 n = 51 
Allergical n = 11 n = 5 
Cardiological n = 5 n = 2 
Dermatological n = 18 n = 7 
Gastrointestinal n = 24 n = 16 
General n = 2 n = 4 
Hematological n = 1 n = 3 
Hepatical n = 1 - 
Ears, nose, through n = 2 n = 2 
Infectious n = 8 n = 4 
Musculosceletal n = 2 - 
Neoplasia n = 1 n = 3 
Nephrological n =1 - 
Nephrological - n = 1 
Neuropsychiatric n = 8 n = 1 
Not defined n = 3 n = 1 
Ophthalmologic n = 1 - 
Pulmonary n = 4 n = 2 
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Table 4: Patient characteristics at baseline depending on the GC use after two years 
GC used after 2 years still on GC no-GC P value 
Number 153 439 - 
Age (years, mean ± SD) 54.6 ± 15.1 53.3 ± 15.1 0.37 
Gender (f/m) 112/41 317/122 0.06 
Follow-up (months, mean ± SD) 63.7 ± 36.5 46.8 ± 37.5 <0.0001 
Disease durations (days, mean ± SD) 181.2 ± 99.7 175.8 ± 96.4 0.56 
SJC at onset (mean ± SD) 7.8 ± 6.1 7.5 ± 5.9 0.66 
TJC at onset (mean ± SD) 8.3 ± 7.2 7.7 ± 6.5 0.32 
DAS-28 at onset (mean ± SD) 4.6 ± 1.6 4.5 ± 1.5 0.30 
RF pos. at onset (n, %*) 107, 69.9 % 281, 64.0%   0.18 
CCP pos. at onset (n, %*) 35, 62.5% 116, 63.4% 0.90 
ESR at onset, mm/h (mean ± SD) 31.2 ± 24.8 27.1 ± 23.3 0.08 
CRP at onset, mg/l (mean ± SD) 27.0 ± 9.1 19.3 ± 12.6 0.45 
Ratingen score at onset 8.1 ± 8.6 8.4 ± 8.6 0.74 
HAQ-DI at onset 1.05 ± 0.73 0.86 ± 0.67 0.005 
f: female 
GC: Glucocorticoids  
m: male 
TJC: Tender joint count 
SJC: Swollen joint count 
RF: rheumatoid factor 
CCP: antibodies to cyclic citrullinated peptides 
CRP: C reactive protein 
n.a. not applicable 
LORA: Late onset rheumatoid arthritis (>60a) 
YORA: Young onset rheumatoid arthritis (<60a) 
* Calculated on patients with available data  
Figure 1: Average GC doses. The average GC doses are demonstrated depending on the 
number of patients initiated on the respected dose 
  
Figure 1Figure 2: DAS-28, HAQ scores and radiographic progression over time. Patient 
groups were analyzed separately for initial GC (dotted grey line, GC patients) and no initial 
GC use (solid black line, no-GC patients). Loess smoothed time-courses of DAS-28 (A), 
Ratingen (B), and (C) HAQ DI scores are depicted per group over 60 months of follow-up.  
 
Figure 2Figure 3. Time to stop/start glucocorticoids and time to start the first biologic 
DMARD. (A) The time to stop glucocorticoids (black line) and the time to start glucocorticoids 
(grey line) in patients initiated with GC (black line) and patients initiated without GCs (grey 
line). The time was assessed in days from the first documented therapy for RA in our cohort 
within the SCQM registry. Patients are presented as percentage of either group. (B) The time 
to initiation of the first biologic DMARD was shown in days after the first visit in patients 
initiated without glucocorticoids (black line) and patients initiated without GCs (grey line). 
Data was shown as percentage per patient group. The time to biologic is demonstrated as 
days after the first visit. 
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